A BiTE idea: engineered antibodies to attack tumors
Cancer Cancer therapy BiTE

A BiTE idea: engineered antibodies to attack tumors

Dr. Talia Henkle
Dr. Talia Henkle

In 10 seconds? Bi-specific T cell engagers (BiTEs) are an emerging cancer treatment strategy that work both to activate anti-cancer T cells and pull them in to kill tumors.

Wow, that sounds high-tech! And it is. BiTEs are essentially super mutant antibodies. We’ve talked a lot about other types of antibody-based cancer treatments like immune checkpoint therapies, but BiTEs take the engineering to the next level.


Get unlimited access to our 3-min Digests and other premium features

Choose your plan:

Sparrow Unlimited

$19/month
  • Includes a free 7-day trial
  • Weekly Recap email
  • Daily updates with the latest research
  • Unlimited access to all Digests
  • Explore all citations and resources
  • Review learnings with Quick Dive
  • The Sparrow Sessions Podcast
  • No advertisement
  • Cancel anytime

We'll send you a reminder email 3 days before your trial ends.

Start my free trial

Sparrow Unlimited

$99/year
  • Save 56% in one, easy payment
  • Includes a free 7-day trial
  • Weekly Recap email
  • Daily updates with the latest research
  • Unlimited access to all Digests
  • Explore all citations and resources
  • Review learnings with Quick Dive
  • The Sparrow Sessions Podcast
  • No advertisement
  • Cancel anytime

We'll send you a reminder email 3 days before your trial ends.

Start my free trial